Verdiva Bio Presents Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th Scientific Sessions

Verdiva Bio Presents Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th Scientific Sessions

VRB-103, a once-weekly oral amylin analog, demonstrated high potency and strong selectivity in vitro for human amylin receptors

VRB-103 expected to enter the clinic in H2 2026 as a monotherapy and in combination with VRB-101, a once-weekly oral GLP-1 analog

VRB-104, a unimolecular amylin and GLP-1 receptor dual agonist, demonstrated potent in vitro activity with strong bias towards amylin and calcitonin receptor activities

Verdiva Bio Limited (“Verdiva Bio” or “the Company”), a clinical-stage biotechnology company advancing a scalable, once-weekly oral obesity product pipeline, today announced new preclinical data for VRB-103, a once-weekly oral amylin receptor-selective amylin analog, and VRB-104, a unimolecular amylin and GLP-1 receptor dual agonist. These data are being presented in poster sessions at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana.